Health
Johnson & Johnson vaccine has 66% efficiency in one dose – Open Access Government
New clinical trial data shows that the Johnson & Johnson vaccine is able to give 66% protection against COVID in one dose – with a normal 85% efficiency
In promising new results from Phase Three, the American Johnson & Johnson vaccine appears to be a strong candidate for Emergency Use Approval. The company will apply for approval in the US by early February.
The UK has a contract to buy 30 million doses, with the US set to receive 100 million. The company is attempting to make a billion doses.
This news comes after the EU approved AstraZeneca for use, after a tense period of accusation and regulatory action.
The ENSEMBLE study
The vaccine trial,…
-
Noosa News23 hours agoBrisbane’s covert cameras catching more than just litterbugs
-
Business9 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Noosa News8 hours agoLune Has Launched a Loyalty Program to Reward Your Love of World-Famous Croissants and Other Tasty Pastries
-
Noosa News23 hours agoAll this country music is giving me the honky-tonk blues